Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1

Elife. 2022 Jul 19:11:e76004. doi: 10.7554/eLife.76004.

Abstract

Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retroviral therapy against HIV. A key challenge is to suppress viral escape, which is more effectively achieved with a combination of bNAbs. Here, we propose a computational approach to predict the efficacy of a bNAb therapy based on the population genetics of HIV escape, which we parametrize using high-throughput HIV sequence data from bNAb-naive patients. By quantifying the mutational target size and the fitness cost of HIV-1 escape from bNAbs, we predict the distribution of rebound times in three clinical trials. We show that a cocktail of three bNAbs is necessary to effectively suppress viral escape, and predict the optimal composition of such bNAb cocktail. Our results offer a rational therapy design for HIV, and show how genetic data can be used to predict treatment outcomes and design new approaches to pathogenic control.

Keywords: HIV combination therapy; broadly neutralizing antibody; evolutionary biology; evolutionary control; human; optimization; physics of living systems; population genetics; stochastic processes; viruses.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Broadly Neutralizing Antibodies
  • HIV Antibodies
  • HIV Infections* / drug therapy
  • HIV-1* / genetics
  • Humans

Substances

  • Antibodies, Neutralizing
  • Broadly Neutralizing Antibodies
  • HIV Antibodies

Grants and funding

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.